BCG immunotherapy - From pathophysiology to clinical practice

Expert Opinion on Drug Safety

Volumn 5, Issue 2, 2006, Pages 225-229

  Tishler, Moshe ^a,c   Shoenfeld, Yehuda ^b,c  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Arthritis; Autoimmunity; BCG vaccination

Indexed keywords

BCG VACCINE; CORTICOSTEROID DERIVATIVE; CYTOKINE; HEAT SHOCK PROTEIN 65; HLA B27 ANTIGEN; HLA DR1 ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; IMMUNOLOGICAL ADJUVANT;

ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTHRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BLADDER CANCER; CANCER IMMUNOTHERAPY; CLINICAL PRACTICE; CLINICAL STUDY; CYSTITIS; CYTOKINE RELEASE; DERMATOMYOSITIS; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; EPIDIDYMITIS; FEVER; HEMATURIA; HEPATITIS; HUMAN; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY ABSCESS; LOW BACK PAIN; MALAISE; NONHUMAN; PATHOPHYSIOLOGY; PNEUMONIA; POLYARTHRITIS; REVIEW; SEPSIS; SUPERFICIAL CANCER; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; BLADDER TUMOR; CHEMICALLY INDUCED DISORDER; IMMUNOLOGY; MYCOBACTERIUM TUBERCULOSIS; PHYSIOLOGY;

ADJUVANTS, IMMUNOLOGIC; ARTHRITIS; AUTOIMMUNE DISEASES; BCG VACCINE; HUMANS; IMMUNOTHERAPY; MYCOBACTERIUM TUBERCULOSIS; URINARY BLADDER NEOPLASMS;

EID: 33644891874     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.5.2.225     Document Type: Review

References (38)

1. JACOBSON DL, GANGE SJ, ROSE NR, GRAHAM NM: Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol. (1997) 84:223-243.
2. SHOENFELD Y: Common infections, idiotypic dysregulation, autoantibody spread and induction of autoimmune diseases. J. Autoimmunity (1996) 9:235-239.
3. COHEN AD, SHOENFELD Y: Vaccine-induced autoimmunity. J. Autommunity (1996) 9:699-703.
4. ASHERSON R, SHOENFELD Y: The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome-molecular mimicry? J. Rheumatol. (2000) 27:12-14.
5. SHOENFELD Y, AHARON-MAOR A, SHERER Y: Vaccination as an additional player in the mosaic of autoimmunity. Clin. Exp. Rheumatol. (2000) 18:1-4.
6. WRAITH DC, GOLDMAN M, LAMBERT PH: Vaccination and autoimmune disease: what is the evidence? Lancet (2003) 362: 1659-1666.
7. TISHLER M, SHOENFELD Y: Vaccination may be associated with autoimmune diseases. Isr. Med. Assoc. J. (2004) 6:430-432.
8. BACH JF: The effect of infections on susceptibility to autoimmune and allergic diseases. N. Engl. J. Med. (2002) 347:911-920.
9. WUCHERPFENNIG KW: Mechanisms for the induction of autoimmunity by infections agents. J. Clin. Invest. (2001) 108:1097-1104.
10. THEOPHILOPOULOS AN, DUMMER W, KONO DW: T cell homeostasis and systemic autoimmunity. J. Clin. Invest. (2001) 108:335-340.
11. TEPLIZKI H, BUSKILA D, ALKAN M, COATES A, BAUMGARTEN A, SHOENFELD Y: ELISA measurement of antibody titer to purified protein derivative and mycobacteria derived phosphooycolipids: tools for diagnosing active pulmonary tuberculosis. Isr. J. Med. Sci. (1987) 23:1121-1124.
12. LINDQVIST KH, COLEMAN RE, OSTERLAND CK: Autoantibodies in chronic pulmonary tuberculosis. J. Chron. Dis. (1997) 22:717-725.
13. SHOENFELD Y, VOLMAR Y, COATES ARM, RAUCH J, SHAUL D, PINHAS J: Monoclonal antituberculosis antibodies react with DNA, and monoclonal antiDNA and autoantibodies react with Mycobacterium tuberculosis. Clin. Exp. Immunol. (1986) 66:255-261.
14. THOMAS CJ, MORRIS JA: Common epitopes between mycobacteria and certain host tissue antigens. Clin. Exp. Immunol. (1985) 61:323-328.
15. GLYNN P, WEEDA D, EDWARDS J, SUCHLINY AJ, CUZNER ML: Humoral immunity in chronic relapsing experimental encephalomyelitis. The major oligoclonal IgG bands are antibodies to mycobacteria. Neurol. Sci. (1982) 57:369-364.
16. HOLOSHITZ J, MATITIAHU A, COHEN IR: Arthritis induced in rata by cloned T lymphocytes responsive to mycobacteria but not to collagen type II. J. Clin. Invest. (1984) 73:211-215.
17. VAN EDEN W, HOLOSHITZ J, NEVO Z, FRENKEL A, KLUJMAN A, COHEN IR: Arthritis induced by a T lymphocyte clone that responds to M. tuberculosis and to cartilage proteoglycans. Proc. Natl. Acad. Sci. USA (1985) 82:5113-5120.
18. HOLOSHITZ J, KLUJMAN A, DRUCKER I et al.: T lymphocytes of rheumatoid arthritis patients show augmented reactivity to a fraction of mycobacteria crossreactive with cartilage. Lancet (1986) 2:305-309.
19. BAXTER AG, HORSFALL AC, HEALY D et al.: Mycobacteria precipitate an SLE-like syndrome in diabetes-prone NOD mice. Immunology (1994) 83:235-248.
20. HORSFALL AC, HOWSON R, SILVEIRA RA, WILLLIAMS DG, BAXTER G: Characterization and specificity of B cell responses in lupus induced by M. bovis in NOD/Lt. mice. Immunology (1998) 95:8.
21. KURTH KR, BOUFFLOUX C, SYLVESTER R, VAN DER MEIJDEN AP, OOSTERLINK W, BRAUSE M: Treatment of superficial bladder tumours: achievements and needs. The EORTC Genitourinary Group. Eur. Urol. (2002) 27(Suppl. 3):1-9.
22. LAMM DL, VAN DER MEIJDEN AP, MORALES A et al.: Incidence and treatment of BCG intravesical therapy in superficial bladder cancer. J. Urol. (1992) 147:598-600.
23. MAS AJ, ROMERA M, VALVERDE GARCIA JM: Articular manifestations after the administration of intravesical BCG. Joint Bone Spine (2002) 69:92-93.
24. SHOENFELD Y, ARON-MAOR A, TANAI A, EHRENFELD M: BCG and autoimmunity. Another two-edged sword. J. Autoimmun. (2001) 16:235-240.
25. MOULY S, BERENBAUM F, KAPLAN G: Remitting seronegative synovitis with pitting edema following intravesical BCG instillation. J. Rheumatol. (2001) 28:1699-1701.
26. PARDALIDIS NP, PAPATSORIS AG, KOSMAOGLOU EV, GEORGANAS C: Two cases of acute polyarthritis secondary to intravesical BCG adjuvant therapy for superficial bladder cancer. Clin. Rheumatol. (2002) 21:536-537.
27. CLAVEL G, GRADOS F, CAYROLLE G et al.: Polyarthritis following intravesical BCG immunotherapy. Report of a case and a review of 20 cases in the literature. Rev. Rhum. Engl. Ed. (1999) 66:115-118.
28. TINAZZI E, FICARRA V, SIMEIONI S, PETERLANA D, LUNARDI C: Reactive arthtritis following BCG immunohterapy for bladder carcinoma. Clin. Rheumatol. (2005) 24:425-427.
29. KASS E, STRAUME S, MUNTHE E: Dermatomyositis after BCG vaccination. Lancet (1978) 1(8072):772.
30. EHRENGUT W. Dermatomyositis and vaccination. Lancet (1978) 1(8072):1040-1041.
31. KASS E, STRAUME S, MELLBYE OJ, MUNTHE E, SALHEIM BG: Dermatomyositis associated with BCG vaccination. Scand. J Rheum. (1979) 8:187-191.
32. BARTOLOME PACHECO MJ, MARTINEZ-TABOADA VM, BLANCO R, RODRIGUEZ-VALVERDE V, VALLE JI, LOPEZ-HOYOS M: Reactive arthritis after BCG immunotherapy: T-cell analysis in peripheral blood and synovial fluid. Rheumatology (2002) 41:1119-1125.
33. PRESCOTT S, JACKSON AM, HAWKYARD SJ, ALEXANDROFF AB, JAMES K: Mechanisms of action of intravesical BCG: local immune mechanisms. Clin. Infect. Dis. (2000) 31:591-593.
34. JACKSON AM, ALEXANDROFF AB, KELLY RW et al.: Changes in urinary cytokines and soluble intracellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after BCG immunotherapy. Clin. Exp. Immunol. (1995) 99:369-375.
35. PRESCOTT S, JAMES K, BUSUTTIL A, HARGREAVE TB, CHISHOLM GD, SMYTH JF: HLA-DR expression by high grade superficial bladder cancer treated with BCG. Br. J. Urol. (1989) 63:264-269.
36. HOLOSHITZ, NAPARSTEK Y, BEN NUN A, COHEN IR: Lines of T lymphocytes induce or vaccinate against autoimmune arthritis. Science (1983) 219:56-58.
37. ABRAHAMSON G, FROLAND SS, MATVIG JB: In vitro mitogen stimulation of synovial fluid lymphocytes from rheumatoid arthritis and juvenile rheumatoid arthritis patients: dissociation between the response to antigens and polyclonal mitogens. Scand J. Immunol. (1978) 7:81-90.
38. ARON-MAOR A, SHOENFELD Y: BCG immunization and the 'Trojan Horse' phenomenon. Clin. Rheum. (2003) 22:6-7.